日本語English简体中文 繁體中文

03692 Hansoh Pharmaceutical Group Company LimitedHANSOH PHARMAHong Kong Stock Exchange

8 posts

Hansoh Pharmaceutical Group Company Limited (03692) at a glance

Code
03692
Company
Hansoh Pharmaceutical Group Company Limited
Local name
HANSOH PHARMA
Market
Hong Kong Stock Exchange
Share price
HK$34.36 -0.66 (-1.88%) Nov 11 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

Hansoh Pharmaceutical Group Company Limited (03692) Stock Price History

Hansoh Pharmaceutical Group Company Limited closed at HK$34.36 on Nov 11, 2026, +8.9% over 1 month, −5.9% over 1 year.

2026-10-19 内部情報(インサイド・インフォメーション)/事業の状況 INSIDE INFORMATION - STR…HK$35.18HK$30.58Oct 12Nov 11
Price5-day MA25-day MAHang Seng IndexDisclosures
1-Month HighHK$35.18Nov 5
1-Month LowHK$30.58Oct 14
1-Week Change+0.7%vs Nov 4
1-Month Change+8.9%vs Oct 9

If you had invested HK$10,000 1 month ago, it would be worth HK$10,887 today (+8.9%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved +0.2%, while this stock moved +8.9%.

Last 10 Trading Days

DateCloseChange% Change
Nov 11 (Wed)HK$34.36−0.66−1.88%
Nov 10 (Tue)HK$35.02+0.16+0.46%
Nov 9 (Mon)HK$34.86+0.06+0.17%
Nov 6 (Fri)HK$34.80−0.38−1.08%
Nov 5 (Thu)HK$35.18+1.06+3.11%
Nov 4 (Wed)HK$34.12+2.18+6.83%
Nov 3 (Tue)HK$31.94−0.04−0.13%
Nov 2 (Mon)HK$31.98−0.38−1.17%
Oct 30 (Fri)HK$32.36−0.72−2.18%
Oct 29 (Thu)HK$33.08+0.94+2.92%
2026-09-16 事業の状況 VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20197 FO…2026-09-21 事業の状況 VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-10374 IN…2026-09-22 事業の状況 VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-2009…2026-09-23 中間報告書 INTERIM REPORT 20262026-09-24 事業の状況 VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF RISVUTATUG…2026-09-27 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATU…2026-10-11 事業の状況 VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION OF AUMO…2026-10-19 内部情報(インサイド・インフォメーション)/事業の状況 INSIDE INFORMATION - STR…HK$36.82HK$30.58Aug 11Nov 11
Price5-day MA25-day MAHang Seng IndexDisclosures
3-Month HighHK$36.82Aug 27
3-Month LowHK$30.58Oct 14
1-Month Change+8.9%vs Oct 9
3-Month Change−1.3%vs Aug 11

If you had invested HK$10,000 3 months ago, it would be worth HK$9,868 today (−1.3%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved −5.2%, while this stock moved −1.3%.

Last 10 Trading Days

DateCloseChange% Change
Nov 11 (Wed)HK$34.36−0.66−1.88%
Nov 10 (Tue)HK$35.02+0.16+0.46%
Nov 9 (Mon)HK$34.86+0.06+0.17%
Nov 6 (Fri)HK$34.80−0.38−1.08%
Nov 5 (Thu)HK$35.18+1.06+3.11%
Nov 4 (Wed)HK$34.12+2.18+6.83%
Nov 3 (Tue)HK$31.94−0.04−0.13%
Nov 2 (Mon)HK$31.98−0.38−1.17%
Oct 30 (Fri)HK$32.36−0.72−2.18%
Oct 29 (Thu)HK$33.08+0.94+2.92%
2026-09-16 事業の状況 VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20197 FO…2026-09-21 事業の状況 VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-10374 IN…2026-09-22 事業の状況 VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-2009…2026-09-23 中間報告書 INTERIM REPORT 20262026-09-24 事業の状況 VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF RISVUTATUG…2026-09-27 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATU…2026-10-11 事業の状況 VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION OF AUMO…2026-10-19 内部情報(インサイド・インフォメーション)/事業の状況 INSIDE INFORMATION - STR…HK$36.82HK$28.56May 11Nov 11
Price25-day MA75-day MAHang Seng IndexDisclosures
6-Month HighHK$36.82Aug 27
6-Month LowHK$28.56Jun 9
3-Month Change−1.3%vs Aug 11
6-Month Change−6.3%vs May 11

If you had invested HK$10,000 6 months ago, it would be worth HK$9,368 today (−6.3%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved −7.9%, while this stock moved −6.3%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026HK$34.36+6.2%
Oct 2026HK$32.36−8.3%
Sep 2026HK$35.30−0.1%
Aug 2026HK$35.34+9.8%
Jul 2026HK$32.18+8.6%
Jun 2026HK$29.62−5.8%
May 2026HK$31.44−15.3%
2026-09-16 事業の状況 VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20197 FO…2026-09-21 事業の状況 VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-10374 IN…2026-09-22 事業の状況 VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-2009…2026-09-23 中間報告書 INTERIM REPORT 20262026-09-24 事業の状況 VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF RISVUTATUG…2026-09-27 事業の状況 VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATU…2026-10-11 事業の状況 VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION OF AUMO…2026-10-19 内部情報(インサイド・インフォメーション)/事業の状況 INSIDE INFORMATION - STR…HK$43.36HK$28.56Nov 11Nov 11
Price25-day MA75-day MAHang Seng IndexDisclosures
52-Week HighHK$43.36Dec 11
52-Week LowHK$28.56Jun 9
Year to Date−4.8%vs Dec 31
From 52-Week High−20.8%Dec 11

If you had invested HK$10,000 1 year ago, it would be worth HK$9,414 today (−5.9%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved −9.7%, while this stock moved −5.9%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026HK$34.36+6.2%
Oct 2026HK$32.36−8.3%
Sep 2026HK$35.30−0.1%
Aug 2026HK$35.34+9.8%
Jul 2026HK$32.18+8.6%
Jun 2026HK$29.62−5.8%
May 2026HK$31.44−15.3%
Apr 2026HK$37.10+4.6%
Mar 2026HK$35.48+1.5%
Feb 2026HK$34.96−9.4%
Jan 2026HK$38.60+7.0%
Dec 2025HK$36.08−10.3%
Nov 2025HK$40.22―
HK$43.00HK$11.38Nov 13, 2023Nov 11, 2026
Price13-week MA26-week MAHang Seng Index
3-Year HighHK$43.00Dec 12, 2025
3-Year LowHK$11.38Jan 29, 2024
Annualized Return+32.8%
Max Drawdown−33.3%

If you had invested HK$10,000 3 years ago, it would be worth HK$23,406 today (+134.1%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved +39.3%, while this stock moved +134.1%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)HK$34.36−4.8%
2025HK$36.08―
HK$43.00HK$9.62Nov 15, 2021Nov 11, 2026
Price13-week MA26-week MAHang Seng Index
5-Year HighHK$43.00Dec 12, 2025
5-Year LowHK$9.62Aug 14, 2023
Annualized Return+14.5%
Max Drawdown−49.4%

If you had invested HK$10,000 5 years ago, it would be worth HK$19,612 today (+96.1%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved −2.9%, while this stock moved +96.1%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)HK$34.36−4.8%
2025HK$36.08―
HK$45.45HK$9.62Jun 10, 2019Nov 11, 2026
Price1-year MA2-year MAHang Seng Index
All-Time HighHK$45.45Jan 2021
All-Time LowHK$9.62Aug 2023
Total Change+76.2%vs Jun 2019
Annualized Return+7.9%

If you had invested HK$10,000 in Jun 2019, it would be worth HK$17,621 today (+76.2%).Price change only; dividends and fees are not included.

Over the same period the Hang Seng Index moved −5.5%, while this stock moved +76.2%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)HK$34.36−5.7%
2025HK$36.44+118.7%
2024HK$16.66+5.7%
2023HK$15.76+6.2%
2022HK$14.84−21.9%
2021HK$19.00−49.0%
2020HK$37.25+46.9%
2019HK$25.35―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Jun 2019). Please check the latest prices before trading.

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No.8 Disclosure 2026/10/19 19:07
内部情報(インサイド・インフォメーション)/事業の状況
INSIDE INFORMATION - STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ROCHE
Delete
No.7 Disclosure 2026/10/11 19:30
事業の状況
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION OF AUMOLERTINIB IN THE EU RESUBMITTED AND VALIDATED BY THE EMA
Delete
No.6 Disclosure 2026/09/27 19:08
事業の状況
VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATUS OF AUMOLERTINIB IN THE EU
Delete
No.5 Disclosure 2026/09/24 20:30
事業の状況
VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA ACCEPTED BY THE NMPA
Delete
No.4 Disclosure 2026/09/23 18:00
中間報告書
INTERIM REPORT 2026
Delete
No.3 Disclosure 2026/09/22 18:00
事業の状況
VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE OF THE NMPA
Delete
No.2 Disclosure 2026/09/21 08:00
事業の状況
VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-10374 IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS HAS MET THE CO-PRIMARY ENDPOINTS
Delete
No.1 Disclosure 2026/09/16 18:00
事業の状況
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20197 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Delete

Write on the Hansoh Pharmaceutical Group Company Limited board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Chinese stocks in English

Chinese Stock Message Board: stocks available in English

Other boards in English